01
Dec

The FDA has branded Takeda’s top late-stage drug prospect–ixazomib (MLN9708), a multiple myeloma treatment designed to succeed the top-selling blockbuster Velcade–as a “breakthrough” therapy deserving VIP status with regulators.

…read more

Source: Takeda scores a ‘breakthrough’ tag for PhIII rare disease drug

    

0 No comments